Concepedia

Guilherme Fleury Perini

GF

Statistics

Publications

16

Citations

1.4K

H-Index

16

Active since

2010

Affiliations

Hospital Israelita Albert Einstein(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Hospital de Clínicas de Porto Alegre

The Maria Sklodowska-Curie National Research Institute of Oncology

Guilherme Fleury Perini is an author at Hospital Israelita Albert Einstein specializing in medicine, oncology, and immunotherapy.

Publications per year

2010–2023

16

Publications

16

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna et al. · Blood · 2020 · 318 citations · Full text

Pharmacy, Health Sciences, Internal Medicine +3

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Philippe Armand, Scott J. Rodig, Catherine Thiéblemont et al. · Journal of Clinical Oncology · 2019 · 259 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 258 citations

Medicine, Oncology, Pharmacology +15

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

Michael Wang, Wojciech Jurczak, Mats Jerkeman et al. · New England Journal of Medicine · 2022 · 216 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170

Pier Luigi Zinzani, Catherine Thiéblemont, Krimo Bouabdallah et al. · Blood · 2023 · 60 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

1–5 of 16